|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
AUGUST 21, 2006
Repligen May Hit "A Home Run"  Shares of Biotech Repligen (RGEN
) popped 25%, to 3, on July 31 when a federal judge ruled that its lawsuit seeking royalties from ImClone Systems (IMCL
) could proceed. The suit claims that ImClone is using Repligen's patented technology (licensed from Massachusetts Institute of Technology) to enhance production of ImClone's colon-cancer drug Erbitux. Eric Ende of Merrill Lynch (MER
) in a report says ImClone could end up paying 1% to 2% of Erbitux sales, which Repligen estimates at $1 billion. But for Elemer Piros of Rodman & Renshaw, Repligen's allure is in its products already on the market, plus others in clinical trials, such as secretin for schizophrenia, and uridine, in Phase 2 trials, for bipolar depression. Repligen's Protein A, to boost antibodies, and SecreFlo, to diagnose pancreatitis and gastrinoma, a rare cancer, had sales of $12.5 million in the year ended Mar. 31, 2006. Stanley Medical Research, which funds work on schizophrenia and bipolar disorder, is conducting the studies. Piros rates the stock, now at 2.62, "outperform/speculative," with a 12-month target of 5. He sees 2007 sales of $14 million. Soros Fund Management and Vanguard Group are among the big investors. Private investor Ronald Chez of Ronald L. Chez Inc. which owns shares, predicts Repligen "will hit a home run" with its new products.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version